Daily Sepsis Research Analysis
Analyzed 27 papers and selected 3 impactful papers.
Summary
Today’s most impactful sepsis-related research spans mechanistic, prognostic, and translational domains. A novel non-covalent mTOR inhibitor suppressed NLRP3–GSDMD-mediated pyroptosis in cellular and murine models, while a multicentre secondary analysis showed that dynamic kinetic eGFR provided more clinically useful prediction of acute kidney disease than a multimarker strategy. A complementary long-term mouse model reproduced persistent inflammation, immunosuppression, and catabolism after sepsis, creating a platform for studying post-sepsis morbidity.
Research Themes
- Targeting inflammasome-mediated pyroptosis
- Dynamic prediction of sepsis-associated acute kidney disease
- Long-term post-sepsis inflammation and immune dysfunction
Selected Articles
1. Non-covalent mTOR inhibition suppresses NLRP3-GSDMD inflammasome-mediated pyroptosis.
This mechanistic study identified CD25, a novel non-covalent small-molecule inhibitor of mTOR, as an inhibitor of NLRP3 inflammasome-mediated pyroptosis. CD25 targeted both mTORC1 and mTORC2, preserved mitochondrial integrity, reduced ASC oligomerization and GSDMD cleavage, and attenuated inflammatory injury in murine lipopolysaccharide-induced sepsis and acetaminophen-induced acute liver injury models.
Impact: The study links dual mTORC1/mTORC2 inhibition to suppression of a central inflammatory cell-death pathway and provides in vivo evidence in a sepsis model. It therefore offers a mechanistically defined therapeutic strategy beyond nonspecific anti-inflammatory treatment.
Clinical Implications: CD25 or related mTOR-directed compounds could become candidates for adjunctive treatment of sepsis-associated inflammatory injury, but clinical use is not yet justified. Pharmacokinetic, toxicity, infection-control, and clinically relevant polymicrobial sepsis studies are required before human trials.
Key Findings
- CD25 suppressed NLRP3 inflammasome-mediated pyroptosis by targeting both mTORC1 and mTORC2.
- CD25 preserved mitochondrial integrity and reduced ASC oligomerization, GSDMD cleavage, and membrane pore formation in macrophages.
- CD25 attenuated inflammatory injury and tissue damage in murine lipopolysaccharide-induced sepsis and acetaminophen-induced acute liver injury models.
Methodological Strengths
- The mechanism was investigated at the level of mTORC1/mTORC2 signaling, mitochondrial integrity, ASC oligomerization, GSDMD cleavage, and membrane pore formation.
- Findings were extended from macrophage experiments to two murine inflammatory injury models, including lipopolysaccharide-induced sepsis.
Limitations
- The evidence is preclinical and derived from cellular and murine models, so efficacy and safety in human sepsis remain unestablished.
- The provided abstract does not report survival endpoints, pharmacokinetic data, dose-response details, or validation in clinically representative polymicrobial sepsis.
Future Directions: Future work should define CD25 pharmacology and toxicity, test its effects on pathogen clearance and organ function in polymicrobial sepsis, establish therapeutic timing and dosing, and evaluate whether combination with current sepsis care improves survival without worsening immunosuppression.
Pyroptosis is an inflammatory form of programmed cell death primarily driven by activation of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, which triggers caspase-1-dependent cleavage of gasdermin D (GSDMD) and subsequent release of pro-inflammatory cytokines. The mechanistic target of rapamycin (mTOR) signaling pathway has emerged as a critical regulator of pyroptosis, yet its precise role in inflammasome activation remains to be incompletely understood. Here, we report that compound CD25, a novel non-covalent small-molecule inhibitor, suppresses NLRP3 inflammasome-mediated pyroptosis by targeting both mTORC1 and mTORC2 pathways.
2. Predictive performance of kinetic eGFR, midregional proadrenomedullin, and H3.1 nucleosomes for acute kidney disease in sepsis: a secondary analysis of a large multicentre randomized controlled trial.
In 690 patients from a multicentre randomized trial, acute kidney disease occurred in 28.4% and was associated with substantially higher 90-day mortality. Although MR-proADM was independently associated with acute kidney disease at baseline, serial changes in kinetic eGFR became the strongest discriminator over time; combined biomarker models provided only modest and inconsistent incremental clinical benefit.
Impact: The study challenges the assumption that increasingly complex biomarker panels necessarily improve risk stratification. It supports a pragmatic, serial assessment of renal function and provides clinically relevant negative evidence against routine reliance on multimarker models.
Clinical Implications: For septic patients at risk of acute kidney disease, clinicians should prioritize serial assessment of dynamic renal function, particularly changes in kinetic eGFR during the first week. MR-proADM may assist early risk assessment, but routine use of H3.1 nucleosomes or multimarker combinations is not supported by clear additional clinical utility.
Key Findings
- Acute kidney disease occurred in 196 of 690 patients, or 28.4%, and was associated with higher 90-day mortality than no acute kidney disease.
- At baseline, only MR-proADM was independently associated with acute kidney disease; at days 2 and 7, changes in kinetic eGFR were independently associated with the outcome.
- The combined model AUC increased from 0.65 at baseline to 0.70 at day 2 and 0.76 at day 7, but added only modest and inconsistent net benefit beyond kinetic eGFR alone.
Methodological Strengths
- The analysis used a relatively large cohort embedded within a multicentre randomized controlled trial.
- It incorporated serial measurements, multivariable adjustment, bootstrap-corrected calibration, decision-curve analysis, and fivefold cross-validation.
Limitations
- This was a secondary observational analysis within a randomized trial rather than a prospective trial testing a biomarker-guided clinical intervention.
- The combined models showed only moderate discrimination, and biomarkers had limited and inconsistent performance for predicting renal recovery.
Future Directions: Future studies should prospectively test kinetic eGFR-guided monitoring and intervention strategies, determine whether earlier recognition of acute kidney disease changes fluid, nephrotoxin, and renal replacement therapy decisions, and validate the findings in diverse sepsis populations.
BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) frequently progresses to acute kidney disease (AKD) and is linked to poor outcomes. We evaluated whether combining biomarkers reflecting complementary pathophysiological domains-histone H3.1 nucleosomes (cellular injury), midregional pro-adrenomedullin (MR-proADM; endothelial dysfunction), and kinetic estimated glomerular filtration rate (kinetic eGFR; dynamic renal function)-improves prediction of AKD and renal recovery. METHODS: This secondary analysis of the multicentre randomized SISPCT trial included 690 patients with sepsis after exclusion of patients with pre-existing renal replacement therapy or missing AKI data. Biomarkers and kinetic eGFR were assessed at baseline, day 2, and day 7.
3. Immunological and histopathological features of secondary injury in a long-term mouse model of persistent inflammation, immunosuppression, and catabolism syndrome.
This study established two long-term murine models of PIICS using cecal ligation and puncture and fecal suspension injection. Survivors displayed persistent inflammatory mediator elevation, reduced anti-inflammatory cytokines, globally suppressed responses to a secondary lipopolysaccharide challenge, and chronic tissue pathology, including intra-abdominal abscesses or granuloma-like masses in some animals.
Impact: The models address an important gap in sepsis research by extending analysis beyond acute mortality to chronic immune dysfunction and tissue injury. Their use of two distinct sepsis induction methods strengthens translational investigation of post-sepsis syndromes.
Clinical Implications: The findings support viewing post-sepsis survivors as a biologically distinct population with persistent immune dysregulation and vulnerability to chronic complications. The models may aid development of immune-restorative, metabolic, and rehabilitation interventions, but they do not yet establish a treatment for patients.
Key Findings
- Both cecal ligation and puncture and fecal suspension injection produced long-term PIICS-like phenotypes over two months.
- PIICS mice showed persistent elevation of G-CSF, IL-7, CCL3, and CCL4 and reduced IL-13 and TGF-β2 at baseline.
- After lipopolysaccharide challenge, PIICS mice had globally suppressed cytokine responses and no mortality, whereas four of thirteen control mice died.
- Histopathology demonstrated pulmonary congestion, splenic macrophage infiltration, portal-vein neutrophil infiltration, and intra-abdominal abscesses or granuloma-like masses in 50% of CLP-PIICS mice.
Methodological Strengths
- The study used two biologically distinct peritonitis-induced sepsis methods to model long-term post-sepsis abnormalities.
- It combined longitudinal survival assessment, multiplex cytokine and chemokine profiling, secondary-challenge testing, and histopathological evaluation.
Limitations
- The study is preclinical, and correspondence between the murine phenotypes and human PIICS remains to be established.
- The abstract does not provide detailed animal numbers by group, sex-specific analyses, functional outcomes, or testing of a therapeutic intervention.
Future Directions: Future studies should validate the models against longitudinal clinical biomarkers and functional outcomes in human sepsis survivors, define sex- and strain-specific effects, and test targeted immune-restorative or metabolic therapies with survival and quality-of-life-related endpoints.
Persistent inflammation, immunosuppression, and catabolism syndrome (PIICS) is a major cause of prolonged morbidity and poor outcomes among critical illness survivors. We established long-term murine PIICS models using two peritonitis-induced sepsis methods-cecal ligation and puncture (CLP) and fecal suspension intraperitoneal injection (FSI)-and investigated their immunological and histopathological features over 2 months. Survivors were defined as PIICS model mice, with unoperated mice serving as controls. Following an intraperitoneal lipopolysaccharide (LPS; 10 mg/kg) challenge, 27 plasma cytokines and chemokines were quantified before and 20 h after administration, and survival was monitored for 14 days.